Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 24 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 6923
Sealed predictions
- SFXN2 in dopamine neurons, braak-0.04 (p 0.927) → -0.72 (p 0.029)receipt 6930
Swarm cases
receipt 6930: SFXN2 in dopamine neurons, braak
- power
- full sample -0.47 (p 0.051, n 18), 95% CI -0.77 to +0.00. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.47 (p 0.051, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.58 (p 0.012, n 18). not the mix.
- skeptic
- leave-one-out range -0.60 to -0.40, sign flips 0; without severely affected donors -0.47 (p 0.051, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SFXN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts